In a patient with metastatic HER2 positive breast cancer who has received prior TDM1 in the adjuvant setting for residual disease, would you consider reintroduction of TDM1?

The patient is intolerant to trastuzumab deruxtecan. In which clinical settings would you consider reintroduction of TDM1?

Answer from: Medical Oncologist at Academic Institution

I would consider re-introduction of TDM1 in the subsequent line setting for metastatic, HER2 positive breast cancer as long as disease free interval between completion of TDM1 and breast cancer relapse is has been long enough. I typically think of 1 year or longer between relapse and completion of a...

Comments

Medical Oncologist at Riverside Methodist Hospitals/OhioHealth
Thank you. Patient has progressed 6 months after c...

Medical Oncologist at Ohio State University
You can try that, although the likelihood of respo...

Medical Oncologist at Riverside Methodist Hospitals/OhioHealth
Thank you.

Please select the option that best describes you:

In a patient with metastatic HER2 positive breast cancer who has received prior TDM1 in the adjuvant setting for residual disease, would you consider reintroduction of TDM1?

Related Questions